Pharmaceutical company running an in-house manufacturing plant at Palghar, Maharashtra, with dedicated production, quality-control, marketing and export functions.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 4 | 4 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 26 | 28 | 20 | 27 | 36 | 46 | 50 | 59 |
| Borrowings | 14 | 15 | 13 | 10 | 8 | 15 | 13 | 19 |
| Other Liabilities | 32 | 28 | 28 | 34 | 36 | 43 | 58 | 59 |
| Total Liabilities | 75 | 76 | 77 | 87 | 96 | 120 | 137 | 153 |
| AssetsFixed Assets | 13 | 15 | 18 | 22 | 21 | 21 | 21 | 20 |
| CWIP | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 2 |
| Other Assets | 60 | 59 | 59 | 64 | 73 | 96 | 114 | 129 |
| Total Assets | 75 | 76 | 77 | 87 | 96 | 120 | 137 | 153 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 5 | 1 | -11 | 6 | 8 | 2 | 5 | 6 |
| Cash from Investing | -4 | -3 | -17 | -2 | -7 | -3 | -3 | -5 |
| Cash from Financing | -1 | 3 | 18 | -6 | -2 | 0 | -1 | -1 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 1 | -2 | -28 | 3 | 2 | 0 | 2 | 1 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (48.6×) and current (32.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 14.7% growth and a 32× exit, ₹43 only delivers your return if you pay ₹37. The price is currently baking in 18% growth.
EPS grows 14.7%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 14.7% | 1.51 |
| FY28 | 14.7% | 1.74 |
| FY29 | 14.7% | 1.99 |
| FY30 | 14.7% | 2.28 |
| FY31 | 14.7% | 2.62 |
| FY32 | 10.3% ·fade | 2.89 |
| FY33 | 6.0% ·fade | 3.07 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.